{
    "1": {
        "workup": {
            "imaging": [
                "CT of the abdomen with or without pelvic CT or MRI",
                "Chest CT or chest X-ray",
                "Bone scan and brain MRI (If clinically indicated )"
            ], 
            "genetic evaluation": ["If multiple renal masses, ≤46 y, or family history"], 
            "others": [
                "History and physical examination",
                "Complete Blood count (CBC)",
                "Comprehensive metabolic panel (serum corrected calcium, serum creatinine, liver function studies, and urinalysis)",
                "Lactate dehydrogenase (LDH)",
                "Urinalysis",
                "Urine cytology, ureteroscopy or percutaneous biopsy (If suspicion of urothelial carcinoma)"
            ]
        }, 
        "treatment": {
            "primary treatment": [
                "Partial nephrectomy", 
                "Total nephrectomy when tumors are not adequate for partial resection due to size and location",
                "Active surveillance for patients with decreased life expectancy or extensive comorbidities", 
                "Small masses should be monitored and treated according to progression" 
            ]
        }, 
        "followup": {
            "active surveillance for T1a": [
                "Annual history", 
                "Annual physical examination",
                "Annual laboratory tests as clinically indicated", 
                "Abdominal imaging with CT o MRI with contrast within 6 months of surveillance initiation with subsequent annual imaging with Ct, MRI or ultrasound (US)", 
                "Annual chest x-ray or CT as clinically indicated", 
                "Repeat chest imaging if intervention is being contemplated",
                "Consider renal mass biopsy at initiation of active surveillance or at follow-up"  
            ], 
            "ablative surgery for T1a": [
                "Annual history", 
                "Annual physical examination",
                "Annual laboratory tests as clinically indicated", 
                "Abdominal CT or MRI with and without contrast at 1 through 6 months to evaluate treatment response followed by yearly abdominal imaging for 5 year, if contrast is not tolerated, MRI is preferred", 
                "Annual chest x-ray or CT for 5 years on patients with biopsy-proven low-risk RCC, non-diagnostic biopsies or no prior biopsy" 
            ], 
            "partial or total nephrectomy": [
                "Annual history", 
                "Annual physical examination",
                "Annual laboratory as clinically indicated", 
                "Baseline abdominal with CT or MRI imaging with within 3-12 months following renal surgery, followed by annual abdominal imaging for 5 years", 
                "Annual chest x-ray or CT for at least 5 years", 
                "More rigorous imaging schedules can be considered if positive margins or adverse pathologic features are found" 
            ]
        }
    }, 
    "2": {
        "workup": {
            "imaging": [
                "CT of the abdomen with or without pelvic CT or MRI",
                "Chest CT or chest X-ray",
                "Bone scan and brain MRI (If clinically indicated)"
            ], 
            "genetic evaluation": ["If multiple renal masses, ≤46 y, or family history"], 
            "others": [
                "History and physical examination",
                "Complete Blood count (CBC)",
                "Comprehensive metabolic panel (serum corrected calcium, serum creatinine, liver function studies, and urinalysis)",
                "Lactate dehydrogenase (LDH)",
                "Urinalysis", 
                "Urine cytology, ureteroscopy or percutaneous biopsy (If suspicion of urothelial carcinoma)"                
            ]
        }, 
        "treatment": {
            "primary treatment": [
                "Partial nephrectomy",
                "Total nephrectomy", 
                "Select patients may be managed by active surveillance" 
            ]
        }, 
        "followup": {
            "Ablative surgery for T1b": [
                "Annual history", 
                "Annual physical examination",
                "Annual laboratory tests as clinically indicated", 
                "Abdominal CT or MRI with and without contrast at 1 through 6 months to evaluate treatment response followed by yearly abdominal imaging for 5 year, if contrast is not tolerated, MRI is preferred", 
                "Annual chest x-ray or CT for 5 years on patients with biopsy-proven low-risk RCC, non-diagnostic biopsies or no prior biopsy" 
            ], 
            "Partial or total nephrectomy": [
                "Annual history", 
                "Annual physical examination",
                "Annual laboratory as clinically indicated", 
                "Baseline abdominal with CT or MRI imaging with within 3-12 months following renal surgery, followed by annual abdominal imaging for 5 years", 
                "Annual chest x-ray or CT for at least 5 years", 
                "More rigorous imaging schedules can be considered if positive margins or adverse pathologic features are found" 
            ]
        }
    }, 
    "3": {
        "workup": {
            "imaging": [
                "CT of the abdomen with or without pelvic CT or MRI",
                "Chest CT or chest X-ray",
                "Bone scan and brain MRI (If clinically indicated)"                
            ], 
            "genetic evaluation": ["If multiple renal masses, ≤46 y, or family history"], 
            "others": [
                "History and physical examination",
                "Complete Blood count (CBC)",
                "Comprehensive metabolic panel (serum corrected calcium, serum creatinine, liver function studies, and urinalysis)",
                "Lactate dehydrogenase (LDH)",
                "Urinalysis",
                "Urine cytology, ureteroscopy or percutaneous biopsy (If suspicion of urothelial carcinoma)"                
            ]
        }, 
        "treatment": {
            "primary treatment": [
                "Radical nephrectomy",
                "Partial nephrectomy is not recommended for patients with locally advanced tumors unless the procedure is technically feasible such as those with small, polar unilateral tumors"
            ], 
            "adjuvant treatment": {
                "Pembrolizumab is recommended for": ["Patients with stage II ccRCC with grade IV sarcomatoid features"]
            }
        }, 
        "followup": {
            "stage II": {
                "Partial or total nephrectomy": [
                    "Annual history", 
                    "Annual physical examination",
                    "Annual laboratory as clinically indicated", 
                    "Baseline abdominal with CT o MRI imaging with within every 6 months for 2 years, then annually for 5 years", 
                    "Annual chest x-ray or CT for at least 5 years", 
                    "More rigorous imaging schedules can be considered if positive margins or adverse pathologic features are found" 
                ]
            }, 
            "stage III": [
                "History every 3 to 6 months for 3 years, then annually for 5 years",
                "Physical examination every 3-6 months for 3 years then annually for 5 years", 
                "Comprehensive metabolic panel and other tests every 3-6 months for 3 years, then annually up to 5 years", 
                "Baseline abdominal CT or MRI imaging within 3-6 months following surgery, then every 3-6 months for 3 years, then annually for 5 years", 
                "If symptoms warrant imaging and site-specific imaging may be performed beyond 5 years" 
            ]
        }
    }, 
    "4": {
        "workup": {
            "imaging": [
                "CT of the abdomen with or without pelvic CT or MRI",
                "Chest CT or chest X-ray",
                "Bone scan and brain MRI (If clinically indicated)"                
            ], 
            "genetic evaluation": ["If multiple renal masses, ≤46 y, or family history"], 
            "others": [
                "History and physical examination",
                "Complete Blood count (CBC)",
                "Comprehensive metabolic panel (serum corrected calcium, serum creatinine, liver function studies, and urinalysis)",
                "Lactate dehydrogenase (LDH)",
                "Urinalysis",
                "Urine cytology, ureteroscopy or percutaneous biopsy (If suspicion of urothelial carcinoma)"
            ]
        }, 
        "treatment": {
            "surgical": [
                "Cytoreductive nephrectomy is recommended for patients with potentially surgically resectable primary tumors prior to systemic therapy", 
                "Palliative nephrectomy is recommended for patients with hematuria or other symptoms related to the primary tumor", 
                "Patients with potentially resectable primary RCC and oligometastatic sites are candidates for nephrectomy and metastasectomy",
                {
                    "Ablative techniques in patients who are not candidates for metastasectomy could be considered in the following patients": [
                        "Patient who initially presents with primary RCC and oligometastatic sites", 
                        "Patients who develop oligometastasis after a prolonged disease-free interval from nephrectomy", 
                        "Oligometastasic sites that are candidates: lung, bone, brain" 
                    ]
                }
            ], 
            "systemic": {
                "Preferred regimens ccRCC": [
                    "Axitinib/Pembrolizumab combination is a category 1 preferred option for all risk groups",
                    "Cabozantinib/Nivolumab combination is a category 1 preferred option for all risk groups",
                    "Lenvatinib/Pembrolizumab combination is a category 1 preferred option for all risk groups", 
                    "Ipilimumab/Nivolumab combination is a category 1 preferred option for poor and intermediate risk patients", 
                    "Cabozantinib is a category 2A preferred treatment for poor and intermediate risk patients"
                ], 
                "Preferred regimens nccRCC": [
                    "Cabozantinib is a category 2A preferred option", 
                    "Sunitinib is a category 2A preferred option"
                ]
            }
        }, 
        "followup": [
            "History every 6 to 16 weeks for patients receiving systemic therapy", 
            "Physical examination every 6 to 16 weeks for patients receiving systemic therapy",
            "Imaging tests with CT or MRI should be performed prior to initiating systemic therapy, followed by imaging studies every 6 to 16 weeks according to patient status and clinician criteria",
            "Annual surveillance scans with CT or MRI can be considered according to clinician criteria", 
            "MRI or CT of head at baseline is recommended as clinically indicated with annual surveillance scan according to clinician criteria", 
            "Additional MRI of spine",
            "Additional bone scans", 
            {
                "Long term follow-up (beyond 5 years)": [
                    "Long term follow-up is considered according to patient performance and preferences", 
                    "Follow up may be performed by primary care physician if appropriate", 
                    "Annual history and physical examination", 
                    "Annual laboratory tests to evaluate renal function and glomerular filtration rate", 
                    "Abdominal imaging may continue with increasing intervals",
                    "Chest imaging may be considered with increasing intervals"
                ]
            }
        ]
    }, 
    "5": {
        "workup": {
            "imaging": [
                "CT of the abdomen with or without pelvic CT or MRI",
                "Chest CT or chest X-ray",
                "Bone scan and brain MRI (If clinically indicated)"
            ], 
            "genetic evaluation": ["If multiple renal masses, ≤46 y, or family history"], 
            "others": [
                "History and physical examination",
                "Complete Blood count (CBC)",
                "Comprehensive metabolic panel (serum corrected calcium, serum creatinine, liver function studies, and urinalysis)",
                "Lactate dehydrogenase (LDH)",
                "Urinalysis",
                "Urine cytology, ureteroscopy or percutaneous biopsy (If suspicion of urothelial carcinoma)"
                
            ]
        }, 
        "treatment": {
            "surgical": [
                "Patients with BHDS, HPRC and TSC may benefit from nephron sparing surgeries or ablative therapies", 
                "Patients with HLRCC should undergo total or radical nephrectomy", 
                 {
                    "Options for patients with PGL/PCC vary by tumor size and histology": [
                        "Smaller, less aggressive tumors are eligible for partial nephrectomy",
                        "Larger, more aggressive tumors are eligible for total nephrectomy"
                    ], 
                    "Options for VHL disease vary by tumor size": [
                        "Tumors approaching 3cm in diameter should undergo partial nephrectomy or ablative therapy"
                    ]
                 }   
            ], 
            "systemic": [
                "Everolimus", 
                "Erlotinib/bevacizumab combination", 
                "Pazopanib"
            ]
        }, 
        "followup": [
            "Females of childbearing age who are planning conception should consider renal imaging prior to pregnancy.",
            "For BAP1-TPDS Abdominal MRI (preferred) or CT with and without IV contrast every 2 years starting at age 30", 
            "For BHDS Abdominal MRI (preferred) or CT with and without IV contrast every 3 years starting at age 20", 
            "For HLRCC Abdominal MRI (preferred) or CT with and without IV contrast every 1 to 2 years starting at age 30", 
            "For PGL/PCC Abdominal MRI (preferred) or CT with and without IV contrast every 4 to 6 years starting at age 12", 
            "For TSC Abdominal MRI (preferred) or CT with and without IV contrast every 3 to 5 years starting at age 12", 
            "For VHL Abdominal MRI (preferred) or CT with and without IV contrast to assess kidneys, pancreas, and adrenals every 2 years starting at age 15" 
        ]
    }
}